Plain-English translation of NCT07141329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a one-year study testing , a new medication for adults with focal onset seizures (seizures that start in one area of the brain). You would have already finished an earlier trial of this same medication to join this study. The research team wants to understand whether the medication is safe and works well when taken long-term.
Earlier studies showed that this medication might help control seizures, but researchers need to confirm that it remains safe and effective over a full year of treatment, and to find the best dose for each person.
You likely qualify if…
You likely don't qualify if…
You would take the medication twice a day for one year. The study starts with an 8–10 week period where your dose is adjusted to find what works best for you, followed by about 10 months of continuing the medication at that dose. At the end, you would gradually stop taking the medication over 4 weeks. You would attend regular visits with the study team to check how you're doing and watch for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Supernus Pharmaceuticals, Inc.
Enrollment target
~100 participants
Started
July 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Supernus Clinical Trials
Supernus Pharmaceuticals, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.